Abstract

Organ-Chips: New Applications, Predictive Validity and Economic Implications

Danny Levner, Chief Technology Officer, Emulate

Organ-on-a-Chip technology continues to evolve both in the breadth of the applications that it addresses, as well as in the depth of its qualification data and understanding of its contexts of use.  In this presentation, we review recent work on modeling immune-cell recruitment for applications in the study of inflammation and immune-oncology.  In addition, we discuss the qualification of the Emulate Liver-Chip using a framework defined by the Innovation and Quality (IQ) consortium, as well as an evaluation of its predictive value against known clinical outcomes using a blinded set of 27 hepatotoxic and non-toxic drugs.  We conclude by exploring the potential financial impact that could result from the adoption of the Emulate Liver-Chip in the small-molecule pharmaceutical industry and estimate that the level of accuracy displayed in this study could generate $3 billion annually due to increased R&D productivity.